PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Thymopentin (TP5) — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymopentin reduced clinical severity, itching and redness more than placebo. · pmid:2185294

In hemodialysis patients who had not responded to hepatitis B vaccination, adding thymopentin to revaccination raised the response rate to 86%, against 27% to 53% with vaccine alone. · pmid:3065661

Identity

PubChem CID 451417: Thymopentin, C30H49N9O9, 679.8 g/mol. · pubchem:451417

CAS registry number 69558-55-0. · pubchem:451417

IUPAC name: (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid. · pubchem:451417

Where the evidence actually sits

Emerging100%

Proportion of the 2 claims about Thymopentin (TP5) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. (1988) · emergingThymopentin therapy reduces the clinical severity of atopic dermatitis. (1990) · emerging19881990

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Thymopentin (TP5) yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Thymopentin therapy reduces the clinical severity of atopic dermatitis. · pmid 2185294 · 1990
    • Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. · pmid 3065661 · 1988
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.